Patent ID: 7427663

Claim:
A method of preparing a cardio myopeptidin from hearts of healthy non-human mammals comprising the steps of: (a) cleaning and cutting the hearts of healthy non-human mammals; (b) homogenizing the hearts by adding sterile distilled water to the myocardium of the hearts of healthy non-human mammals which is cleaned and cut, thereby creating homogenate; (c) freezing and thawing the homogenate for 3 to 4 cycles; (d) heating the homogenate to 65 to 95° C.; (e) filtering the homogenate using a plate-and-frame filter to obtain a coarse filtrate, and removing a residue resulting from the filtering; (f) ultra-filtering the coarse filtrate with a hollow-fiber column to obtain a fine filtrate having a molecular weight of less than 12000 Da; (g) ultra-filtering the fine filtrate using an ultrafiltration membrane to obtain the cardio myopeptidin solution with a molecular weight in the range from 2000 to 8000 Da; and (h) concentrating the cardio myopeptidin solution by reverse osmosis to obtain a concentrated cardio myopeptidin solution; (i) testing the quality of concentrated cardio myopeptidin solution; and, (j) filtering aseptically, filling, and lyophilizing the concentrated cardio myopeptidin solution to obtain a solution comprising: 75% to 90% of cardio myopeptidin; 6% to 15% of free amino acid; less than 2% of ribonucleic acid; and, less than 7.5% of deoxyribonucleic acid, wherein the cardio myopeptidin shows four to five principal peaks on an HPLC analysis spectrum, having a relative peak area of more than 85%, and wherein the cardio myopeptidin reduces the effect of ischemia reperfusion in the heart.